Paper Search Console

Home Search Page Alphabetical List About Contact

Journal Title

Title of Journal: J Cancer Res Clin Oncol

Search In Journal Title:

Abbravation: Journal of Cancer Research and Clinical Oncology

Search In Journal Abbravation:



Search In Publisher:



Search In DOI:



Search In ISSN:
Search In Title Of Papers:

Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT

Authors: Xueling Ou, Shaohui Cai, Peng Liu, Jun Zeng, Yuwen He, Xinyao Wu, Jun Du,

Publish Date: 2007/10/02
Volume: 134, Issue:5, Pages: 525-533
PDF Link


Dendritic cell (DC)-based cancer vaccines are currently being evaluated as novel anti-tumor vaccination strategies, but in some cases, they are demonstrated to have poor clinical efficacies than anticipated. A potential reason is immune tolerance due to the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO). The aim of this study was to determine whether blocking the activity of IDO might improve the anti-tumor efficacy of DC/Lewis lung carcinoma (LLC) fusion vaccine applied to the mouse LLC model.To prepare the DC/LLC fusion vaccine, DCs were fused with LLC using polyethylene glycol (PEG) as described. The IDO expression in the DC/LLC fusion vaccine and in the vaccinated mice was detected by western blot (WB) and/or immunohistochemical (IHC) analysis. This fusion vaccine, as a single agent or in combination with 1-methyl-tryptophan (1-MT, an IDO inhibitor), was administered to LLC mice. The anti-tumor efficacy in different treatment was determined by regular observation of tumor development and the level of splenic cytotoxic T lymphocyte (CTL) response, which was examined by lactate dehydrogenase (LDH) release.In the LLC mice, we observed that IDO-positive cells were extensively accumulated in tumor draining lymph nodes (TDLNs). Furthermore, WB and IHC analysis results showed that vaccination with fusion DC/LLC cells alone caused significant up-regulation of IDO in spleens. 1-MT enhanced the anti-tumor efficacy elicited by DC/LLC fusion vaccine via delaying the tumor development and inducing stronger splenic CTL responses.



Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2
  2. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases
  3. The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study
  4. Salvage therapy with topotecan in heavily pretreated ovarian cancer patients
  5. Resveratrol plays dual roles in pancreatic cancer cells
  6. Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases
  7. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth
  8. Colour junctions as predictors of radiosensitivity: X-irradiation combined with gemcitabine in a lung carcinoma cell line
  9. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation
  10. Interstitial growth as an aggressive growth pattern in primary lung cancer
  11. Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy
  12. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer
  13. Prostate transitional zone volume-based nomogram for predicting prostate cancer and high progression prostate cancer in a real-world population
  14. Imbalance in redox status is associated with tumor aggressiveness and poor outcome in lung adenocarcinoma patients
  15. Genetic polymorphism of ESR1 rs2881766 increases breast cancer risk in Korean women

Search Result:

Help video to use 'Paper Search Console'